X4 Pharmaceuticals (XFOR) Other financing activities (2018 - 2025)
X4 Pharmaceuticals (XFOR) posted Other financing activities of $52000.0 for Q4 2025, down 61.48% on a QoQ basis from $135000.0 in Q4 2024, and down 61.48% year-over-year from $135000.0 in Q4 2024.
X4 Pharmaceuticals (XFOR) Other financing activities (2018 - 2025) Analysis & Trends
X4 Pharmaceuticals' Other financing activities history runs 4 years deep, the most recent figure standing at $52000.0 for Q4 2025.
- Quarterly Other financing activities fell 61.48% year-over-year to $52000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $187000.0 (down 32.0% YoY) and the FY2025 annual result came in at $98000.0, down 66.67% from the prior year.
- Other financing activities was $52000.0 for Q4 2025 at X4 Pharmaceuticals, down from $135000.0 in the prior quarter.
- Across five years, Other financing activities topped out at $135000.0 in Q4 2024 and bottomed at $52000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | X4 Pharmaceuticals | 167.69 Mn | -49.36 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Dec 31, 2024 | 135,000.00 |
| Mar 31, 2019 | 113,000.00 |
| Mar 31, 2019 | 113,000.00 |
| Dec 31, 2018 | 27,000.00 |
| Dec 31, 2018 | 27,000.00 |